ArticleToxicology reports2026
Comparative hepatoprotective effects of Benzene Sulfonamide Derivatives in a rat model of ethylene glycol-induced liver injury.
Article in Toxicology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethylene glycol (EG), an alcohol derivative, is metabolized into toxic compounds contributing to liver damage. This study investigated the therapeutic potential of two benzene sulfonamide derivatives-SBCL and SBF-against EG-induced hepatotoxicity in rats. Liver damage was induced using 0.12 ml of 5 % EG, followed by oral administration of the test compounds (10 mg/kg) every 48 h for 21 days. Rats were divided into six groups (n = 5 per group): a negative control (NEG), a positive control (EG), and four treatment groups-SBCL in healthy rats (SBCL-NEG), SBCL in EG-treated rats (SBCL-EG), SBF in healthy rats (SBF-NEG), and SBF in EG-treated rats (SBF-EG). The two compounds influenced liver biomarkers, including ALT, ALP, serum oxalate, and citrate, as well as oxidative stress indicators such as nitric oxide (NO), lipid peroxidation (LPO), protein carbonyls (PC), and superoxide dismutase (SOD) activity. SBCL and SBF reduced ALT levels in healthy rats, indicating potential hepatoprotective effects under normal conditions. However, SBCL was associated with elevated oxidative stress markers and reduced antioxidant activity in EG-treated rats, suggesting possible pro-oxidant effects in degenerative liver tissue. In contrast, SBF showed a more stable protective profile in healthy and EG-treated rats. These findings recommend that benzene sulfonamide derivatives, especially SBF, may have therapeutic relevance in managing EG-induced liver injury. SBCL may exhibit context-dependent toxicity under pathological conditions. Overall, the study supports the potential of these compounds in modulating liver toxicity, but additional research is needed to clarify their safety in pathological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.